Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis
DiscussionThe expected outcome of the study is to obtain first reliable data on a hypothesis-driven therapeutic option in severe and difficult-to-treat autoimmune encephalitis. If treatment with bortezomib is beneficial in these cases, this will be the basis for implementation in the current guidelines.Trial registrationClinicaltrials.gov,NCT03993262. Registered June 20, 2019;German Clinical Trials Register, DRKS00017497. (Source: Trials)
Source: Trials - July 7, 2020 Category: Research Source Type: clinical trials
Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)
Conditions: Therapeutic Drug Monitoring; Subarachnoid Hemorrhage; Intracerebral Hemorrhage Interventions: Drug: Piperacillin/tazobactam; Drug: Meropenem; Drug: Daptomycin; Drug: Ceftobiprole; Drug: Linezolid; Drug: Vancomycin; Drug: Fluconazol; Drug: Acyclovir; Drug: Gentamicins; Drug: Amikacin; Drug: Ganciclovir Sponsor: Azienda Sanitaria-Universitaria Integrata di Udine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2019 Category: Research Source Type: clinical trials
A Randomized Trial of Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis
Condition: Herpes Simplex Virus Keratitis Interventions: Drug: oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily; Drug: oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops Sponsor: New York University School of Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 13, 2018 Category: Research Source Type: clinical trials
